Alveo Technologies said this week that it has received the CE mark for its Be.well COVID-19 Flex Test.
The test is for use with the firm’s Be.well isothermal nucleic acid amplification platform and will be available soon in the UK and other parts of Europe, the Alameda, California-based company said, adding that it plans to submit the test to the US Food and Drug Administration for Emergency Use Authorization. Alveo was also named one of 20 finalists by the Xprize in December in a $6 million competition to develop rapid tests for detecting SARS-CoV-2.
The Be.well platform is being developed for use at home for the detection of infectious diseases with results available in 30 minutes, according to Alveo’s website. Along with COVID-19, the firm is developing tests for the flu and respiratory syncytial virus for use with the Be.well platform.
Prior to the coronavirus pandemic, Alveo said that it planned to commercialize its infectious disease diagnostic platform, which is capable of detecting multiple viral pathogens at a low cost, for the point-of-care testing market.